Recently, we examined the prognosis of cisplatin-based neoadjuvant chemotherapy in 58 bladder cancer patients treated with M-VAC and GC therapy using the results of an immunohistochemical study of ERCC1. This evidence concerns the gene ERCC1 and urinary bladder cancer.